Flow cytometry to detect bone marrow involvement by follicular lymphoma

IF 2.3 3区医学 Q3 MEDICAL LABORATORY TECHNOLOGY

Cytometry Part B: Clinical Cytometry Pub Date : 2022-10-31 DOI:10.1002/cyto.b.22098

Mercè Aren, Silvia Marce, Rebeca Jurado, Gustavo Tapia, Lluís Puigdefabregues, Minerva Raya, Montserrat Cortes, Montse Garcia-Caro, Jordi Junca, Pablo Mozas, Esther Viñets, Marta Cabezon, Esther Plensa, Milos Miljkovic, Juan-Manuel Sancho, José-Tomas Navarro, Lurdes Zamora, Marc Sorigue

{"title":"Flow cytometry to detect bone marrow involvement by follicular lymphoma","authors":"Mercè Aren, Silvia Marce, Rebeca Jurado, Gustavo Tapia, Lluís Puigdefabregues, Minerva Raya, Montserrat Cortes, Montse Garcia-Caro, Jordi Junca, Pablo Mozas, Esther Viñets, Marta Cabezon, Esther Plensa, Milos Miljkovic, Juan-Manuel Sancho, José-Tomas Navarro, Lurdes Zamora, Marc Sorigue","doi":"10.1002/cyto.b.22098","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>High-quality data on bone marrow involvement (BMI) assessed by flow cytometry (FC) in follicular lymphoma (FL) is lacking.</p>\n </section>\n \n <section>\n \n <h3> Aims</h3>\n \n <p>We set up a prospective protocol with a 10-color tube and acquisition of 500.000 leukocytes on a Nav flow cytometer for evaluation of BMI in FL by FC.</p>\n </section>\n \n <section>\n \n <h3> Materials and methods</h3>\n \n <p>FC was compared with a combination of histopathology and <i>IGH</i> gene rearrangement, which were considered the gold standard. We also compared BMI by FC with PET.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Fifty-two patients were included (median 67 years, 54% female). BMI by FC was seen in 35 (67%), with a median involvement of 1.2% (interquartile range: 0.3%–7%) of leukocytes. Comparison with the gold standard revealed two false negatives and two false positives (potentially true involvement undetected by the gold standard). BMI by PET was seen in 14/46 (30%). Immunophenotype of FL in the bone marrow was highly heterogeneous. The most common phenotypic abnormality was dim expression of CD19 (>0.5 log loss in 30% of patients). CD10 was negative in 13 (37%) and incompletely positive (overlap with the negative population) in a further 8 (28%) while entirely positive only in 14 (48%). Other abnormalities (loss of CD20, gain or loss of CD79b, expression of CD43, and substantial loss of CD45) were rare. Computational analysis by means of FlowSOM confirmed the heterogeneous phenotype, with FL from different patients clustering in unrelated metaclusters.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>BMI by FL was frequent and immunophenotype was heterogeneous. However, this protocol enabled detection of FL in bone marrow in the vast majority of patients with bone marrow involvement by the gold standard.</p>\n </section>\n </div>","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2022-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cyto.b.22098","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cytometry Part B: Clinical Cytometry","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cyto.b.22098","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 2

Abstract

Background

High-quality data on bone marrow involvement (BMI) assessed by flow cytometry (FC) in follicular lymphoma (FL) is lacking.

Aims

We set up a prospective protocol with a 10-color tube and acquisition of 500.000 leukocytes on a Nav flow cytometer for evaluation of BMI in FL by FC.

Materials and methods

FC was compared with a combination of histopathology and IGH gene rearrangement, which were considered the gold standard. We also compared BMI by FC with PET.

Results

Fifty-two patients were included (median 67 years, 54% female). BMI by FC was seen in 35 (67%), with a median involvement of 1.2% (interquartile range: 0.3%–7%) of leukocytes. Comparison with the gold standard revealed two false negatives and two false positives (potentially true involvement undetected by the gold standard). BMI by PET was seen in 14/46 (30%). Immunophenotype of FL in the bone marrow was highly heterogeneous. The most common phenotypic abnormality was dim expression of CD19 (>0.5 log loss in 30% of patients). CD10 was negative in 13 (37%) and incompletely positive (overlap with the negative population) in a further 8 (28%) while entirely positive only in 14 (48%). Other abnormalities (loss of CD20, gain or loss of CD79b, expression of CD43, and substantial loss of CD45) were rare. Computational analysis by means of FlowSOM confirmed the heterogeneous phenotype, with FL from different patients clustering in unrelated metaclusters.

Conclusion

BMI by FL was frequent and immunophenotype was heterogeneous. However, this protocol enabled detection of FL in bone marrow in the vast majority of patients with bone marrow involvement by the gold standard.

Abstract Image

查看原文本刊更多论文

流式细胞术检测滤泡性淋巴瘤累及骨髓

背景:目前尚缺乏流式细胞术(FC)评估滤泡性淋巴瘤(FL)骨髓受累(BMI)的高质量数据。我们建立了一种前瞻性的方案，采用10色试管和在Nav流式细胞仪上采集50万个白细胞，通过FC评估FL的BMI。材料和方法将FC与组织病理学和IGH基因重排相结合的方法进行比较，后者被认为是金标准。我们还比较了FC和PET的BMI。结果纳入52例患者，中位年龄67岁，女性占54%。35例(67%)出现FC BMI，白细胞中位数为1.2%(四分位数范围:0.3%-7%)。与金本位制相比，发现了两个假阴性和两个假阳性(金本位制未检测到的潜在真实参与)。PET测得BMI为14/46(30%)。FL在骨髓中的免疫表型是高度异质性的。最常见的表型异常是CD19的低表达(30%的患者丢失0.5 log)。CD10阴性13例(37%)，不完全阳性8例(28%)，完全阳性14例(48%)。其他异常(CD20的缺失、CD79b的获得或缺失、CD43的表达和CD45的大量缺失)是罕见的。通过FlowSOM计算分析证实了异质表型，来自不同患者的FL聚集在不相关的元聚类中。结论FL引起的BMI多发，且免疫表型具有异质性。然而，该方案能够在绝大多数骨髓受累的患者中通过金标准检测骨髓中的FL。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cytometry Part B: Clinical Cytometry 医学-病理学

CiteScore

6.80

自引率

32.40%

发文量

审稿时长

>12 weeks

期刊介绍： Cytometry Part B: Clinical Cytometry features original research reports, in-depth reviews and special issues that directly relate to and palpably impact clinical flow, mass and image-based cytometry. These may include clinical and translational investigations important in the diagnostic, prognostic and therapeutic management of patients. Thus, we welcome research papers from various disciplines related [but not limited to] hematopathologists, hematologists, immunologists and cell biologists with clinically relevant and innovative studies investigating individual-cell analytics and/or separations. In addition to the types of papers indicated above, we also welcome Letters to the Editor, describing case reports or important medical or technical topics relevant to our readership without the length and depth of a full original report.